Trinity Biotech
TRIB
19 hedge funds and large institutions have $6.51M invested in Trinity Biotech in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
5% less funds holding
Funds holding: 20 → 19 (-1)
13% less capital invested
Capital invested by funds: $7.5M → $6.51M (-$984K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
53% less call options, than puts
Call options by funds: $8K | Put options by funds: $17K
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$32.2K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$20.2K |
| 3 |
AWS
Atria Wealth Solutions
New York
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$479K |
| 2 |
Renaissance Technologies
New York
|
-$54.2K |
| 3 |
LPL Financial
San Diego,
California
|
-$20.7K |
| 4 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$14.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
TRIB Hedge Fund Activity: Q4 2022 in Review
19 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2022, worth a combined $6.51M — down 13% from $7.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TRIB and 2 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 2 added.
The largest buyer was Hunter Associates Investment Management, adding an estimated $32.2K. The largest seller was Stonehill Capital Management, cutting an estimated $479K.
- 19 institutional investors held Trinity Biotech (TRIB) as of Q4 2022, down from 20 in Q3 2022.
- Funds reported $6.51M of Trinity Biotech stock for Q4 2022, down 13% quarter-over-quarter.
- 2 funds opened new Trinity Biotech positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Trinity Biotech buyer in Q4 2022 was Hunter Associates Investment Management, an estimated $32.2K added.
- The largest Trinity Biotech seller in Q4 2022 was Stonehill Capital Management, an estimated $479K sold.
Based on aggregated 13F filings for Q4 2022.